Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Oct 7 · above the Ichimoku cloud · RSI 100 (overbought) · MACD below its signal
None of the 29 investors followed here reported a position in RGRX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a RGRX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for RGRX.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 66.7 | 20.0 | 0.0 | 0.0 | 83.3 | 0.0 | 0.0 | +266.7% | ||
| 2025 | 0.0 | 0.0 | 0.0 | -85.7 | 0.0 | 0.0 | 2400.0 | -96.0 | 80400.0 | -99.9 | 0.0 | 50.0 | −78.6% |
| 2024 | 0.0 | 0.0 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | +16.7% |
| 2023 | 7.9 | -12.2 | -20.2 | -33.3 | -43.0 | -33.5 | -4.7 | -36.8 | 6.3 | -100.0 | 350.0 | 33.3 | −100.0% |
| 2022 | 70.3 | -4.6 | -30.8 | -13.9 | 16.1 | -13.9 | 19.4 | -13.0 | -13.0 | 21.4 | -5.9 | -13.2 | −13.2% |
| 2021 | 9.0 | 52.6 | -66.2 | -8.0 | 31.5 | -10.4 | -1.3 | -18.1 | -24.7 | 9.0 | 11.1 | -20.0 | −64.0% |
| 2020 | 92.9 | -11.1 | -20.8 | 35.8 | 12.4 | 8.7 | 20.6 | 50.0 | -30.2 | 39.3 | 6.4 | -24.6 | +217.9% |
| 2019 | -14.2 | -2.3 | 81.5 | -21.6 | 8.1 | -10.0 | -7.2 | -1.2 | -5.5 | -10.3 | -5.3 | 5.6 | −9.7% |
| 2018 | 58.8 | 0.0 | -18.5 | 0.0 | -9.1 | 0.0 | 5.0 | -11.9 | -2.7 | -5.6 | -29.4 | 29.2 | −8.8% |
| 2017 | -2.3 | -0.0 | -6.5 | -0.9 | -2.5 | -3.6 | 4.6 | -0.9 | 17.9 | -18.2 | -15.7 | -25.3 | −46.4% |
| 2016 | 0.0 | 0.0 | 58.6 | 0.3 | -44.3 | 19.2 | -24.3 | 13.4 | -6.0 | -14.7 | 4.7 | -5.3 | −27.9% |
| 2015 | 10.4 | 53.2 | 6.1 | 74.1 | 6.7 | -25.0 | 16.7 | 0.4 | -1.6 | -1.2 | 1.8 | 5.4 | +205.6% |
| 2014 | 367.3 | -20.8 | -0.1 | 1.1 | -8.5 | 0.5 | -26.9 | -9.5 | 6.5 | 26.8 | -9.0 | -3.7 | +169.2% |
| 2013 | -2.2 | -13.8 | 20.0 | -5.6 | -5.9 | -2.5 | 2.6 | -12.5 | -2.4 | -5.9 | -5.9 | -11.6 | −39.9% |
| 2012 | 10.7 | -16.1 | 30.8 | 17.6 | -20.5 | 0.6 | -6.9 | 3.4 | -15.6 | -7.7 | 0.0 | -25.8 | −36.4% |
| 2011 | 3.6 | -7.0 | -5.7 | 14.0 | -16.7 | 0.0 | 7.9 | 26.8 | 19.2 | -3.5 | -44.8 | -15.2 | −36.4% |
| 2010 | 1.8 | 1.8 | 0.0 | -0.4 | -39.9 | -21.0 | 0.0 | 0.0 | 16.8 | -21.0 | 0.8 | -12.4 | −60.0% |
| 2009 | -36.4 | -36.0 | 8.3 | 55.8 | -16.0 | -11.8 | -3.3 | -3.4 | 51.8 | -18.8 | -8.7 | -12.7 | −53.4% |
| 2008 | -9.0 | 9.9 | -7.0 | 88.2 | -14.3 | -13.3 | -11.6 | 8.8 | -9.6 | -14.2 | 23.7 | -1.7 | +18.0% |
| 2007 | 15.1 | -8.1 | 5.5 | -1.7 | -4.4 | -2.3 | 3.3 | -17.9 | -5.1 | -23.7 | 11.6 | -30.6 | −51.2% |
No analyst coverage for this instrument.
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tß4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee's Pharmaceutical Group for the development and marketing of Tß4-related products; and HLB Therapeutics for the development and marketing of RGN-259, and RGN-137 for dermal wound healing. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in December 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.
No recent headlines.